Listed on the TSX Venture Exchange (TSXV: RX) BioSyent is a profitable growth oriented speciality pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are proven safe and effective, and have track records of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

BioSyent continues to search for products to in-license or acquire that match the following criteria: 

- Are unique and occupy a niche in the market; 
- Provide novel technological or therapeutic advantages to patients and healthcare professionals;
- Are backed by strong partners who hold defendable intellectual property rights.

Backed by the success of our products, for two consecutive years (2012 & 2013) BioSyent was named to the TSX Venture Top 50 strong performing companies.

BioSyent has been named one of Canada’s fastest growing companies by PROFIT Magazine.

Health Care

Pharmaceutical

Therapeutics

BioSyent Inc

BioSyent Inc's headquarters in Toronto, Canada

Description

People (16)

Joost Van Der Mark

Navid Ashrafi

Robert J. March

Stephen Wilton

Peter Lockhard

Sharan Raghubir

Pamela Jaycock

Jennifer Truong

Joe Holloway

Sara Colman

Susan Jankus

Andrew Watts

Gillian Brook

Jeff Vandevalk

Ritu Kapoor

Jonathan Eccles

Jobs